Pomalyst vs Trelegy Ellipta
Side-by-side drug price comparison from Medicare Part D data
Verdict
Trelegy Ellipta costs 98% less per claim than Pomalyst ($380.00 vs $17250.00). Neither drug has a generic alternative available. Total Medicare spending: Pomalyst at $3.3B vs Trelegy Ellipta at $2.9B.
| Metric | Pomalyst | Trelegy Ellipta |
|---|---|---|
| Avg Cost per Claim Average cost Medicare pays per prescription claim | $17,250 | $380* |
| Total Medicare Spending Total Medicare Part D spending on this drug | $3.3B | $2.9B |
| Total Claims | 192,000 | 7,560,000 |
| Year-over-Year Change Price change from prior year (lower is better for patients) | 4.7%* | 19.8% |
| Generic Available | No | No |
| Condition | Cancer | Asthma/COPD |
| Total Beneficiaries | 18,000 | 865,000 |
Trelegy Ellipta costs 98% less per claim than Pomalyst ($380.00 vs $17250.00). Neither drug has a generic alternative available. Total Medicare spending: Pomalyst at $3.3B vs Trelegy Ellipta at $2.9B.
Explore More
Comparing Pomalyst and Trelegy Ellipta on U.S. Medicare prescription-drug pricing requires lining up the underlying CMS Medicare Part D Drug Spending data data side by side. The table above runs the comparison on the canonical fields; the narrative below identifies the factor or factors that drive the most meaningful difference between the two.
Practical use of the comparison: read the data above, then drill into the individual Pomalyst and Trelegy Ellipta detail pages for the underlying breakdown. A pairwise comparison answers the relative question; the per-entity pages answer the absolute question.
Source: CMS Medicare Part D Spending, 2026.